Free tool
FAERS Monitor: Cefazolin and Dextrose
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050779 or its brand name (Cefazolin and Dextrose, Cefazolin Sodium). Reports on generic versions are filed under their own applications.
Reports
3,023
Serious
2,872
95% of reports
Hospitalization
1,452
Death reported
362
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaphylactic shock270
- anaphylactic reaction164
- hypotension154
- pyrexia137
- rash131
- anaemia92
- erythema92
- nausea88
- off label use84
- pneumonia84
- urticaria84
- tachycardia83
- diarrhoea74
- pruritus74
- hepatic function abnormal72
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 29 |
| 2005 | 55 |
| 2006 | 44 |
| 2007 | 43 |
| 2008 | 53 |
| 2009 | 27 |
| 2010 | 50 |
| 2011 | 106 |
| 2012 | 192 |
| 2013 | 45 |
| 2014 | 56 |
| 2015 | 74 |
| 2016 | 117 |
| 2017 | 83 |
| 2018 | 121 |
| 2019 | 148 |
| 2020 | 148 |
| 2021 | 139 |
| 2022 | 296 |
| 2023 | 318 |
| 2024 | 357 |
| 2025 | 319 |
| 2026 | 203 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,136 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaphylactic shockSignal | 270 | 73.6 | 65.7 | 19,097 |
| anaphylactic reactionSignal | 164 | 20.7 | 17.8 | 3,055 |
| hepatic function abnormalSignal | 72 | 13.4 | 10.7 | 817 |
| tachycardiaSignal | 83 | 6.5 | 5.3 | 382 |
| hypotensionSignal | 154 | 5.3 | 4.6 | 544 |
| urticariaSignal | 84 | 3.5 | 2.8 | 148 |
| anaemiaSignal | 92 | 3.4 | 2.7 | 151 |
| erythemaSignal | 92 | 3.1 | 2.5 | 131 |
| pyrexiaSignal | 137 | 2.8 | 2.3 | 154 |
| rashSignal | 131 | 2.1 | 1.8 | 75 |
| pneumonia | 84 | 1.8 | 1.5 | 30 |
| pruritus | 74 | 1.3 | 1.1 | 6 |
| diarrhoea | 74 | 0.8 | 0.6 | 4 |
| nausea | 88 | 0.8 | 0.6 | 6 |
| off label use | 84 | 0.7 | 0.5 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.